Literature DB >> 24452611

Erythrina abyssinica prevents meningoencephalitis in chronic Trypanosoma brucei brucei mouse model.

Johnson Nasimolo1, Stephen Gitahi Kiama, Peter Karuri Gathumbi, Andrew Ndegwa Makanya, John Maina Kagira.   

Abstract

Human African trypanosomiasis is prevalent in Sub-sahara African countries that lie between 14° North and 29° south of the equator. Sixty million people are at risk of infection. Trypanosoma brucei gambesience occurs in West and Central Africa while Trypanosoma brucei rhodesience occurs in East and Southern Africa. The neurological stage of the disease is characterized by neuroinflammation. About 10% of patients treated with the recommended drug, melarsoprol develop post treatment reactive encephalopathy, which is fatal in 50% of these patients, thus melarsoprol is fatal in 5% of all treated patients. This study was aimed at establishing the potential activity of Erythrina abyssinica in reducing neuroinflammation following infection with Trypanosoma brucei brucei. Swiss white mice were divided into ten groups, two control groups and eight infected groups. Infected mice received either methanol or water extract of Erythrina abyssinica at 12.5, 25, 50 or 100 mg/kg body weight. Parasite counts were monitored in peripheral circulation from the third day post infection up to the end of the study. Brains were processed for histology, immunohistochemistry scanning and transmission electron microscopy. Following infection, trypanosomes were observed in circulation 3 days post-infection, with the parasitaemia occurring in waves. In the cerebrum, typical brain pathology of chronic trypanosomiasis was reproduced. This was exhibited as astrocytosis, perivascular cuffing and infiltration of inflammatory cells into the neuropil. However, mice treated with Erythrina abyssinica water extract exhibited significant reduction in perivascular cuffing, lymphocytic infiltration and astrocytosis in the cerebrum. The methanol extract did not have a significant difference compared to the non-treated group. This study provides evidence of anti-inflammatory properties of Erythrina abyssinica and may support its wide use as a medicinal plant by various communities in Kenya.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452611     DOI: 10.1007/s11011-014-9488-5

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  55 in total

1.  A simple and sensitive antigen retrieval method for free-floating and slide-mounted tissue sections.

Authors:  Y Jiao; Z Sun; T Lee; F R Fusco; T D Kimble; C A Meade; S Cuthbertson; A Reiner
Journal:  J Neurosci Methods       Date:  1999-11-15       Impact factor: 2.390

2.  Limitation of Trypanosoma brucei parasitaemia results from density-dependent parasite differentiation and parasite killing by the host immune response.

Authors:  K M Tyler; P G Higgs; K R Matthews; K Gull
Journal:  Proc Biol Sci       Date:  2001-11-07       Impact factor: 5.349

3.  Anti-trypanosomal effects of aqueous extract of Ocimum gratissimum (Lamiaceae) leaf in rats infected with Trypanosoma brucei brucei.

Authors:  M Adamu; C O Nwosu; R I S Agbede
Journal:  Afr J Tradit Complement Altern Med       Date:  2009-05-07

4.  Pathology of the disease in sheep produced experimentally by Trypanosoma brucei.

Authors:  B O Ikede; G J Losos
Journal:  Vet Pathol       Date:  1972       Impact factor: 2.221

5.  Light microscopic neuropathology of long-term experimental Trypanosoma brucei gambiense infection in the rat.

Authors:  B Chirimwami; E A Van Marck; J M Brucher; P Mulumba; M Wery; P L Gigase
Journal:  Ann Soc Belg Med Trop       Date:  1988-09

Review 6.  Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression.

Authors:  W S Griffin; J G Sheng; M C Royston; S M Gentleman; J E McKenzie; D I Graham; G W Roberts; R E Mrak
Journal:  Brain Pathol       Date:  1998-01       Impact factor: 6.508

7.  IL-6 detection in multiple sclerosis brain.

Authors:  D Maimone; G C Guazzi; P Annunziata
Journal:  J Neurol Sci       Date:  1997-02-27       Impact factor: 3.181

8.  Screening of some Kenyan medicinal plants for antibacterial activity.

Authors:  Cyrus G Wagate; James M Mbaria; Daniel W Gakuya; Mark O Nanyingi; P G Kareru; Anne Njuguna; Nduhiu Gitahi; James K Macharia; Francis K Njonge
Journal:  Phytother Res       Date:  2010-01       Impact factor: 5.878

9.  Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal.

Authors:  Vincent Jamonneau; Hamidou Ilboudo; Jacques Kaboré; Dramane Kaba; Mathurin Koffi; Philippe Solano; André Garcia; David Courtin; Claude Laveissière; Kouakou Lingue; Philippe Büscher; Bruno Bucheton
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

10.  Antioxidant activity, total phenolic and total flavonoid contents of whole plant extracts Torilis leptophylla L.

Authors:  Naima Saeed; Muhammad R Khan; Maria Shabbir
Journal:  BMC Complement Altern Med       Date:  2012-11-16       Impact factor: 3.659

View more
  3 in total

1.  Medicinal plants used for the management of respiratory diseases in Zimbabwe: Review and perspectives potential management of COVID-19.

Authors:  Elliot Nyagumbo; William Pote; Bridgett Shopo; Trust Nyirenda; Ignatius Chagonda; Ruvimbo J Mapaya; Fabian Maunganidze; William N Mavengere; Cephas Mawere; Ian Mutasa; Emmanuel Kademeteme; Alfred Maroyi; Tafadzwa Taderera; Michael Bhebhe
Journal:  Phys Chem Earth (2002)       Date:  2022-09-21       Impact factor: 3.311

Review 2.  Traditional Medicinal Uses, Phytoconstituents, Bioactivities, and Toxicities of Erythrina abyssinica Lam. ex DC. (Fabaceae): A Systematic Review.

Authors:  Samuel Baker Obakiro; Ambrose Kiprop; Elizabeth Kigondu; Isaac K'Owino; Mark Peter Odero; Scolastica Manyim; Timothy Omara; Jane Namukobe; Richard Oriko Owor; Yahaya Gavamukulya; Lydia Bunalema
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-03       Impact factor: 2.629

Review 3.  Herbal Drugs from Sudan: Traditional Uses and Phytoconstituents.

Authors:  Mohamed Gamaleldin Elsadig Karar; Nikolai Kuhnert
Journal:  Pharmacogn Rev       Date:  2017 Jul-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.